Citius Oncology (NASDAQ:CTOR) Shares Down 2.5% – Should You Sell?

Citius Oncology, Inc. (NASDAQ:CTOR) shares fell 2.5% during mid-day trading on Friday . The company traded as low as $1.15 and last traded at $1.17. 45,075 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 101,126 shares. The stock had previously closed at $1.20.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on shares of Citius Oncology in a report on Wednesday, November 27th. They set a “buy” rating and a $3.00 target price for the company.

Citius Oncology Trading Down 2.5 %

The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34. The business’s fifty day moving average price is $1.18.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings results on Friday, February 14th. The company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Citius Oncology

An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC bought a new position in Citius Oncology, Inc. (NASDAQ:CTOR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,699 shares of the company’s stock, valued at approximately $26,000. Institutional investors own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.